Presented by: Lars Nilsson, Ph.D., Lund University, and Christoph Johann, Ph.D., Wyatt Technology
Presented Live: February 24, 2021
The analysis of aggregates of therapeutic proteins is crucial to ensure efficacy and patient safety. Typically, the analysis is performed in the finished formulation to ensure that aggregates are not present. An important question is, however, what happens to therapeutic proteins, with regard to oligomerization and aggregation, after they have been administrated intravenously.
This webinar features a demonstration of the separation of whole blood, plasma, and serum using asymmetric-flow field-flow fractionation (AF4) with a minimum of sample pre-treatment. The analysis of therapeutic antibodies in blood plasma using AF4 with fluorescence and surface plasmon resonance (SPR) detection is demonstrated in pre-clinical research with further potential for use in clinical trials, following implementation of appropriate quality systems. The results show the suitability and strength of AF4 for blood protein analysis and opens new important routes for the analysis and characterization of therapeutic proteins in blood.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.